全文获取类型
收费全文 | 3697篇 |
免费 | 195篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 39篇 |
儿科学 | 65篇 |
妇产科学 | 49篇 |
基础医学 | 519篇 |
口腔科学 | 53篇 |
临床医学 | 445篇 |
内科学 | 803篇 |
皮肤病学 | 32篇 |
神经病学 | 378篇 |
特种医学 | 91篇 |
外科学 | 434篇 |
综合类 | 20篇 |
一般理论 | 1篇 |
预防医学 | 336篇 |
眼科学 | 95篇 |
药学 | 276篇 |
中国医学 | 1篇 |
肿瘤学 | 263篇 |
出版年
2023年 | 20篇 |
2022年 | 47篇 |
2021年 | 75篇 |
2020年 | 45篇 |
2019年 | 45篇 |
2018年 | 52篇 |
2017年 | 45篇 |
2016年 | 77篇 |
2015年 | 98篇 |
2014年 | 116篇 |
2013年 | 150篇 |
2012年 | 229篇 |
2011年 | 268篇 |
2010年 | 133篇 |
2009年 | 179篇 |
2008年 | 263篇 |
2007年 | 297篇 |
2006年 | 315篇 |
2005年 | 307篇 |
2004年 | 226篇 |
2003年 | 218篇 |
2002年 | 183篇 |
2001年 | 29篇 |
2000年 | 28篇 |
1999年 | 26篇 |
1998年 | 45篇 |
1997年 | 34篇 |
1996年 | 39篇 |
1995年 | 22篇 |
1994年 | 24篇 |
1993年 | 39篇 |
1992年 | 17篇 |
1991年 | 14篇 |
1990年 | 15篇 |
1989年 | 14篇 |
1988年 | 16篇 |
1987年 | 9篇 |
1986年 | 14篇 |
1985年 | 5篇 |
1984年 | 6篇 |
1983年 | 11篇 |
1982年 | 9篇 |
1981年 | 5篇 |
1980年 | 11篇 |
1979年 | 5篇 |
1973年 | 4篇 |
1940年 | 3篇 |
1935年 | 4篇 |
1932年 | 8篇 |
1931年 | 3篇 |
排序方式: 共有3900条查询结果,搜索用时 15 毫秒
61.
62.
63.
64.
65.
66.
67.
Fiona?J?CharlsonEmail author Andrew?E?Moran Greg?Freedman Rosana?E?Norman Nicolas?JC?Stapelberg Amanda?J?Baxter Theo?Vos Harvey?A?Whiteford 《BMC medicine》2013,11(1):250
Background
Cardiovascular disease and mental health both hold enormous public health importance, both ranking highly in results of the recent Global Burden of Disease Study 2010 (GBD 2010). For the first time, the GBD 2010 has systematically and quantitatively assessed major depression as an independent risk factor for the development of ischemic heart disease (IHD) using comparative risk assessment methodology.Methods
A pooled relative risk (RR) was calculated from studies identified through a systematic review with strict inclusion criteria designed to provide evidence of independent risk factor status. Accepted case definitions of depression include diagnosis by a clinician or by non-clinician raters adhering to Diagnostic and Statistical Manual of Mental Disorders (DSM) or International Classification of Diseases (ICD) classifications. We therefore refer to the exposure in this paper as major depression as opposed to the DSM-IV category of major depressive disorder (MDD). The population attributable fraction (PAF) was calculated using the pooled RR estimate. Attributable burden was calculated by multiplying the PAF by the underlying burden of IHD estimated as part of GBD 2010.Results
The pooled relative risk of developing IHD in those with major depression was 1.56 (95% CI 1.30 to 1.87). Globally there were almost 4 million estimated IHD disability-adjusted life years (DALYs), which can be attributed to major depression in 2010; 3.5 million years of life lost and 250,000 years of life lived with a disability. These findings highlight a previously underestimated mortality component of the burden of major depression. As a proportion of overall IHD burden, 2.95% (95% CI 1.48 to 4.46%) of IHD DALYs were estimated to be attributable to MDD in 2010. Eastern Europe and North Africa/Middle East demonstrate the highest proportion with Asia Pacific, high income representing the lowest.Conclusions
The present work comprises the most robust systematic review of its kind to date. The key finding that major depression may be responsible for approximately 3% of global IHD DALYs warrants assessment for depression in patients at high risk of developing IHD or at risk of a repeat IHD event.68.
Gorlani A Brouwers J McConville C van der Bijl P Malcolm K Augustijns P Quigley AF Weiss R De Haard H Verrips T 《AIDS research and human retroviruses》2012,28(2):198-205
There is an urgent global need for preventive strategies against HIV-1 infections. Llama heavy-chain antibody fragments (VHH) are a class of molecules recently described as potent cross-clade HIV-1 entry inhibitors. We studied the potential of a VHH-based microbicide in an application-oriented fashion. We show that VHH can be inexpensively produced in high amounts in the GRAS organism Saccharomyces cerevisiae, resulting in a very pure and endotoxin free product. VHH are very stable under conditions they might encounter during transport, storage, or use by women. We developed active formulations of VHH in aqueous gel and compressed and lyophilized tablets for controlled release from an intravaginal device. The release profile of the VHH from, e.g., a vaginal ring suggests sufficient bioavailability and protective concentration of the molecule at the mucosal site at the moment of the infection. The ex vivo penetration kinetics through human tissues show that the VHH diffuse into the mucosal layer and open the possibility to create a second defense layer either by blocking the HIV receptor binding sites or by blocking the receptors of immune cells in the mucosa. In conclusion, our data show that VHH have a high potential for HIV-1 microbicide application because of their low production costs, their high stability, and their favorable release and tissue penetration properties. 相似文献
69.